FDA found sterile drug manufacturing and investigation failures at Jubilant HollisterStier in Kirkland.
What happened
FDA inspected the Kirkland, Quebec, facility from October 20 to November 3, 2025. It found sterile manufacturing design and smoke-study problems, media fills that did not simulate long interventions, discoloration on surfaces in the sterile filling area, and environmental monitoring excursions that were not investigated promptly. It also found a visible particulate investigation still open five months later while more batches were made on the same line.
What FDA found
Sterile manufacturing design and airflow smoke tests did not adequately protect exposed vials from microbial contamination.
21 CFR 211.113(b)Media fills did not simulate the longest interventions seen in commercial filling, so they did not show the process could withstand those risks.
21 CFR 211.113(b)Discoloration on surfaces below filters and inside a filling line was not explained, and the product impact review did not check visible particulate inspection data.
21 CFR 211.113(b)Environmental monitoring excursions, including mold on personnel, were not investigated promptly, and some non-product areas were not investigated at all.
21 CFR 211.192A visible particulate investigation remained open five months while more batches were made on the same line without a final root cause.
21 CFR 211.192The quality system was not effective; FDA said the quality unit lacked enough authority or did not carry out its duties.
21 CFR parts 210 and 211
What FDA wants
FDA tells the company to respond in writing within 15 working days with corrective actions, including an independent contamination-risk assessment, remediation plans, and an assessment of its investigation and corrective-action systems. It also says to correct violations promptly and warns that approvals may be withheld or U.S. admission refused.
Who should pay attention
- companies that rely on sterile drugs made at this Kirkland facility
- quality teams at other sterile injectable manufacturers
- U.S. supply-chain and drug-shortage planners
This is a summary. Read the original letter on fda.gov.